NHI 2 |
Catalog No.GC50151 |
NHI 2 est un puissant inhibiteur de la LDH-A. NHI 2 est un agent anti-glycolytique efficace. NHI 2 a le potentiel pour la recherche sur les maladies cancéreuses.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1269802-97-2
Sample solution is provided at 25 µL, 10mM.
LDHA inhibitor; reduces lactate production in HeLa cells. Inhibits cell growth of LPC006 and PANC-1 cells in vitro. Enhances the antiproliferative effects of Gemcitabine on LPC006 and PANC-1 cells. Also inhibits ferroptosis.
Maftouh et al (2014) Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcit. against pancreatic cancer cells in hypoxia. Br.J.Cancer 110 172 PMID:24178759 |Calvaresi et al (2013) Dual targeting of the Warburg effect with a glucose-conjugated lactate dehydrogenase inhibitor. Chembiochem 14 2263 PMID:24174263 |Granchi et al (2013) Assessing the differential action on cancer cells of LDH-A inhibitors based on the N-hydroxyindole-2-carboxylate (NHI) and malonic (Mal) scaffolds. Org.Biomol.Chem. 11 6588 PMID:23986182 |Jacobsen et al (2018) APD-containing cyclolipodepsipeptides target mitochondrial function in hypoxic cancer cells. Cell Chem.Biol. 25 1337 PMID:30122371
Average Rating: 5
(Based on Reviews and 7 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *